Professor, Internal Medicine, UC, Davis School of Medicine
Hematology
Dr. Robert T. O'Donnell, MD
|
|
Give Review
Robert T. O'Donnell is an expert in the field of Hematology. He graduated from Loyola University Chicago Stritch School of Medicine. He over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Robert O'Donnell is a published physician. He has 87 publications published. The most current publication "Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates."
Publications
- Histone deacetylase inhibition enhances the Lymphomacidal activity of the anti-CD22 monoclonal antibody HB22.7.
- Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin Lymphoma.
- Targeting CD22 in B-cell Malignancies: Current Status and Clinical Outlook.
- Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell Acute lymphoblastic leukemia.
- Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's Lymphoma.
- The CD22 Antigen is Broadly Expressed on Lung Cancer Cells and is a Target for Antibody-based Therapy.
- Disulfide cross-linked micelles for the targeted delivery of vincristine to B-cell Lymphoma.
- The HB22.7 Anti-CD22 Monoclonal Antibody Enhances Bortezomib-mediated Lymphomacidal Activity in a Sequence Dependent Manner.
- The Bs20x22 anti-CD20-CD22 bispecific antibody has more Lymphomacidal activity than do the parent antibodies alone.
- Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD).
- Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's Lymphoma xenograft mouse model.
- Imaging and pharmacokinetics of (64)Cu-DOTA-HB22.7 administered by intravenous, intraperitoneal, or subcutaneous injection to mice bearing non-Hodgkin's Lymphoma xenog...
- Effect of antiLymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's Lymphoma.
- Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate Cancer.
- Nuclear localizing sequences: an innovative way to improve targeted radiotherapy.
- Splenic volume change and nodal tumor response in non-Hodgkin's Lymphoma patients after radioimmunotherapy using radiolabeled Lym-1 antibody.
- High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast Cancer by using a MUC-1 monoclonal antibody, m170, linked to in...
- Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry.
- An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of Cancer clinical trial costs in California.
- Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in Lymphoma-bearing mice.
- Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate Cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N...
- Anti-CD22 ligand-blocking antibody HB22.7 has independent Lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in Lymphoma xenografts.
- Early diagnosis and successful treatment of a patient with transfusion-associated GVHD with autologous peripheral blood progenitor cell transplantation.
- Combined modality radioimmunotherapy for human prostate Cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6.
- Transcranial Doppler (TCD) screening for stroke prevention in sickle cell Anemia: pitfalls in technique variation.
- Prevalence of Müllerian duct anomalies detected at ultrasound.
- Sonographic detection of uterine and ovarian abnormalities in female survivors of Wilms' tumor treated with radiotherapy.
- Abdominal injury score: a clinical score for the assignment of risk in children after blunt trauma.
- Off-pump and on-pump coronary artery bypass grafting are associated with similar graft patency, myocardial ischemia, and freedom from reintervention: long-term follow-...
- Active site architecture of polymorphic forms of human glutathione S-transferase P1-1 accounts for their enantioselectivity and disparate activity in the glutathione c...
- Interstitial pneumonitis following rituximab therapy for Immune thrombocytopenic purpura (ITP).
- Neuronally restricted RNA splicing regulates the expression of a novel GABAA receptor subunit conferring atypical functional properties [corrected; erratum to be publi...
- Obstetrical brachial plexus palsy (OBPP) outcome with conservative management.
- Treatment of refractory large granular lymphocytic Leukemia with 2-chlorodeoxyadenosine.
- Palliative embolization of fibrosarcoma for control of tumor-induced hypoglycemia.
- Vincristine for Thrombocytopenic purpura.
- Secondary supratentorial primitive neuroectodermal tumor following irradiation in a patient with low-grade Astrocytoma.
- How much heparin? A simple in vitro test.
- Treatment of refractory fludarabine induced autoImmune haemolytic with the anti-CD20 monoclonal antibody rituximab.
- Potential use of amino acid cocktails to reduce renal tubular reabsorption of radioconjugates.
- A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin''s Lymphoma.
- Epidemiology of venous thromboembolism in 9489 patients with Malignant glioma.
- Practical determination of organ S values for individual patients for therapy.
- Phase I trial of high-dose tamoxifen in combination with cisplatin in patients with lung Cancer and other advanced malignancies.
- A phase II trial of concomitant interferon-alpha-2b and granulocyte-macrophage colony-stimulating factor in patients with advanced renal cell Carcinoma.
- Imaging for improved prediction of myelotoxicity after radioimmunotherapy.
- Enhancement of 67Cu-2IT-BAT-LYM-1 therapy in mice with human Burkitt's Lymphoma (Raji) using interleukin-2.
- Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiolabeled MAbs.
- Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labe...
- Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin''s Lymphoma: a pilot study.
- Prospective evaluation of Cancer clinical trial accrual patterns: identifying potential barriers to enrollment.
- Transfer of copper from a chelated 67Cu-antibody conjugate to ceruloplasmin in Lymphoma patients.
- Prediction of myelotoxicity using semi-quantitative marrow image scores.
- Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources.
- Impact of splenomegaly on therapeutic response and I-131-LYM-1 dosimetry in patients with B-lymphocytic malignancies.
- Peripheral blood stem cell mobilization for hematopoietic support of radioimmunotherapy in patients with Breast carcinoma.
- A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's Lymphoma.
- Radioimmunotherapy for advanced breast Cancer using I-131-ChL6 antibody.
- Antibody responses to macrocycles in Lymphoma.
- Dosimetry-based therapy in metastatic breast Cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A.
- Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate Cancer.
- Radiolabeled anti-Lymphoma antibodies.
- Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's Lymphoma.
- Efficacy and toxicity of radioimmunotherapy with (90)Y-DOTA-peptide-ChL6 for PC3-tumored mice.
- Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast Cancer xenografts.
- Strategies for developing effective radioimmunotherapy for solid Tumors.
- Milestones in the development of Lym-1 therapy.
- 67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's Lymphoma.
- Importance of temporal relationships in combined modality radioimmunotherapy of Breast carcinoma.
- Effects of radiolysis on yttrium-90-labeled Lym-1 antibody preparations.
- Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body.
- Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates.
- L6 monoclonal antibody binds prostate Cancer.
- A preliminary cell kinetics model of thrombocytopenia after radioimmunotherapy.
- Radioimmunotherapy for breast Cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial.
- Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji Lymphoma xenografts.
- A revolution in the treatment of non-Hodgkin's Lymphoma.
- Stability of monoclonal antibodies, Lym-1 and ChL6, and 2IT-BAD-Lym-1 immunoconjugate with ultra freezer storage.
- Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated Lymphoma.
- Preclinical evaluation of chimeric L6 antibody for the treatment of Kaposi's sarcoma with radioimmunotherapy.
- Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance deLivery of radioimmunotherapy.
- Metabolite production in patients with Lymphoma after radiometal-labeled antibody administration.
- Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate Cancer.
- Treatment of non-Hodgkin''s Lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy.
- Phosphatase inhibition augments anti-CD22-mediated signaling and cytotoxicity in non-hodgkin''s Lymphoma cells.
- Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human Lymphoma xenografts.
Schools
Loyola University Of ChicagoStritch School Of Medicine
University Ca Davis Med Center
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of California Davis -
Loyola University Chicago Stritch School of Medicine
Hospital
-
University of California, Davis Medical Center
Drug Facts
| NPI NUMBER | 1386627586 | |
| NPPES Provider LastName | O'DONNELL | |
| NPPES Provider FirstName | ROBERT | |
| NPPES Provider ZIPCode | 958172229 | |
| NPPES Provider State | CA | |
| Specialty Description | Gynecological/Oncology | |
| Total Claim Count | 360.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1386627586 |
| Last Name Of The Provider | O'DONNELL |
| First Name Of The Provider | ROBERT |
| View All |
Similar Doctors
|
|
Dr. Edward W. Hearn, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sidney A. Scudder, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David R. Gandara, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Karen L. Kelly, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Derick H. Lau, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hoa C. Duong, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sarah J. Perez, MD |
|
|
Dr. Chong-Xian Pan, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Michael M. Aguilar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Primo N. Lara Jr., MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Randeep S. Sangha, MD |
|
|
Karimireddy J. Reddy, MB
This Doctor is OpenDoctor Recommended.
|